{
  "drug_status": {
    "Lucicebtide": "success"
  },
  "extractions": {
    "Lucicebtide": {
      "drug_name": "Lucicebtide",
      "drug_classes": [
        "C/EBPβ Antagonist"
      ],
      "selected_sources": [
        "abstract_title"
      ],
      "confidence_score": 1.0,
      "extraction_details": [
        {
          "extracted_text": "antagonism of C/EBPβ",
          "normalized_form": "C/EBPβ Antagonist",
          "class_type": "MoA",
          "evidence": "Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition",
          "source": "abstract_title",
          "rules_applied": [
            "Rule 1: Prioritize abstract title",
            "Rule 3: Maintain Title Case",
            "Rule 11: Include biological target",
            "Rule 15: Capture Agonist/Antagonist with target"
          ]
        }
      ],
      "extraction_method": "tavily",
      "reasoning": "The abstract title explicitly identifies lucicebtide as an antagonist of C/EBPβ. Following Rule 1, since the drug class is mentioned in the abstract title, it is prioritized over all other sources. Following Rule 3, Rule 11, and Rule 13, the target and modality are formatted as 'C/EBPβ Antagonist' using Title Case and the specific target mentioned.",
      "success": true
    }
  }
}